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Abstract
Cluster headache (CH) is a neurovascular headache syndrome characterized by headache attacks
that occur with a circadian and circannual periodicity. The calculated prevalence of CH in
reproductive-aged women is 7.5 of 100,000 women. Although data suggest that CH during
pregnancy is a relatively rare condition, when it does occur, attacks remain unchanged in character
and severity in the majority of patients. Thus, treatment of CH in pregnant and lactating women
may remain a significant therapeutic challenge. This manuscript briefly reviews the epidemiology
of CH in women, and then focuses on treatment options for both acute and preventative
management of CH in pregnant and lactating women.
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Introduction
Cluster headache (CH) is a neurovascular headache syndrome characterized by headache
attacks that occur with a circadian and circannual periodicity. Typical attacks are unilateral
in location, of extreme intensity but short duration, and associated with autonomic
dysfunction [1].
There is a relative paucity of information pertaining to CH in pregnancy and lactation,
largely not without cause. CH is a relatively rare, primary headache disorder that affects an
estimated 0.06% of the population, with an overall male:female ratio of approximately 2.5:1
[1, 2]. However, during reproductive years, the male preponderance is roughly 7:1 [2]. Thus,
in reproductive-aged women, this results in a calculated prevalence of CH of only 7.5 of
100,000 women. To further reduce the population of interest, there are reports of relative
hypo-fertility in women with CH [3, 4]. Specifically, when onset of attacks preceded a first
pregnancy, women had significantly (P<0.01) fewer children than those who were parous
before their first attack [5].
Nevertheless, the strong male preponderance in CH has seen progressive decreases over
recent decades, and varies in relationship to age of onset. The decline in the male:female
ratio has been attributed to an increase in the number of female sufferers, an increase that
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has paralleled declines in the male:female ratios in smoking and in employment outside the
home [6].
In addition, there is also variability in the gender ratio of CH based on the age of onset.
When the onset of CH is between the ages of 30–49 years (when women are typically
premenopausal), the gender ratio for episodic CH is 7.2:1 and an impressive 11:1 for chronic
CH. After the age of 50 years, this gender disparity shrinks to only 2.3:1 for episodic CH
cases and disappears altogether (0.6:1) for chronic CH [2].
Although the relative rarity of these headaches in premenopausal-aged women is suggestive
of a possible protective effect of estrogen, the course of CH does not appear to be modified
by the hormonal fluctuation of the menstrual cycle [3]. However, it is important to
remember that even the lowest estrogen concentrations encountered in a normal menstrual
cycle are many times higher than those found in postmenopausal women, when estrogen
concentrations are typically lower than those of even age-matched males.
Data are conflicting as to whether CH improves in pregnancy or remains unchanged, with
most studies limited by small numbers and retrospective design. To illustrate the issue, one
review examined 249 patients with CH [4]. Only 34 patients were female, of whom only
eight had experienced pregnancy since the onset of CH; six of those eight reported remission
of cluster in the (very) high estrogen environment of pregnancy. In another study of 143
women with CH, 111 had been pregnant; only 19 of these patients reported CH attacks
during a pregnancy, with the majority reporting no increase in severity or frequency of those
attacks compared with attacks outside of pregnancy [5]. Another study found that only 5%
of women with CH experienced attacks during pregnancy [1]. However, it is of note that
pregnancy was associated with a change in the women's seasonal pattern of attacks, such
that expected seasonal clusters did not occur when pregnant. Taken together, all of these
studies suggest that CH during pregnancy is a relatively rare condition, but when it does
occur, attacks remain unchanged in character and severity.
Nonpharmacologic Approaches
Nonpharmacologic approaches should always be considered first-line therapy, a practice that
is particularly important in pregnancy and lactation. Specifically, pregnant women should be
strongly encouraged to stop both smoking and excessive alcohol ingestion for a multitude of
medical reasons, including potential injury to the fetus, but also because CH has been shown
to have a close association with both smoking and alcohol ingestion [7].
Another nonpharmacological consideration for management of CH during pregnancy and
lactation is screening for sleep apnea. Sleep apnea prevalence has been reported as high as
80% in patients with episodic CH attacks [7, 8]. Reports have also suggested that obstructive
sleep apnea (OSA) may be more common in pregnancy, particularly in the third trimester; it
also may be associated with preeclampsia and harm to the fetus [8]. A reasonable approach
would be to ask all cluster patients to complete a screener for OSA, such as the Berlin
Questionnaire or the Pittsburgh Sleep Quality Index (See Appendix 1, 2 and 3), with referral
for formal evaluation and treatment by a sleep specialist for those who screen positively or
whose attacks worsen, especially in pregnancy [9]. Nasal continuous positive airway
pressure or an appropriate dental device may then be appropriate considerations in those
who do have OSA.
Treatment in Pregnancy
Many effective treatments exist for both abortive and preventive care of patients with CH.
But when the patient is pregnant or lactating, collaboration among the headache specialist,
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obstetrician, and pediatrician is encouraged to ensure safety of both the mother and her
developing baby.
Ideally, drugs would not be taken in pregnancy; however, circumstances often favor their
judicious use. To illustrate current usage of drugs in pregnancy, a survey of 1,000 pregnant
women in southwest France showed that 99% of the women received a prescription for at
least one drug during pregnancy, with a mean of 13.6 medications per woman [10]. Drugs in
Category X (fetal risk outweighs benefit) were prescribed to 1.6% of the women; 59% had a
prescription from Category D (fetal risk exists, but benefits may be acceptable); and 79%
were exposed to drugs for which information about safety in pregnancy was not available
from animal or human studies.
The US Food and Drug Administration drug categories in pregnancy are reviewed in Table
1. Category A is almost nonexistent and includes products such as prenatal vitamins and
thyroid hormone in physiologic replacement doses. In Categories B and C, harm has not
been shown in humans, whereas in Categories D and X, harm has been shown in humans. In
many cases, the difference between Categories B and C may hinge on how high the dose
was pushed in laboratory animals.
Beyond these rating categories, treatment decisions may be guided by physiologic studies of
drug transport, adverse events reporting, and experience collected from prospective
pregnancy registries. In the absence of prospective drug treatment trials in pregnancy—
which are rarely if ever conducted—product inserts generally do not recommend use in
pregnancy. However, counterbalancing issues of relative safety, it is important to remember
that the pain of CH is excruciating, even to the point of suicide, in patients with intractable
or untreated CH [11].
As with pharmacologic treatment of any medical disorder in pregnancy, a detailed
discussion of the risks and benefits of treatment of CH in pregnancy is essential. In general,
the number of different medications as well as their dosage and frequency should be kept to
a minimum.
The European Federation of Neurological Societies (EFNS) published evidence-based
consensus recommendations for the treatment of CH in the general (nonpregnant) population
[12]. The drugs of first choice were oxygen (100%, with a flow at least 7 L/min over 15
min) and sumatriptan (6 mg subcutaneous). Both of these may also be options in pregnancy
for the treatment of CH.
Inhalation of pure oxygen via a non-rebreathing mask is the preferred first-line treatment
due to the lack of obvious contraindications to either mother or fetus [13, 14]. Delivery of
100% oxygen during CH attacks results in cerebral vasoconstriction and stimulates synthesis
of serotonin in the central nervous system. A clinical trial of oxygen therapy in CH found
complete resolution of pain within 20 min in six of the seven oxygen-treated subjects,
whereas none of the six control subjects achieved pain resolution. It has also been suggested
that higher flow oxygen rates up to 15 L per minute may be of benefit when lower rates have
been unsuccessful [15].
If oxygen treatment is insufficient, injectable or intranasal sumatriptan may be considered.
Sumatriptan has been widely used over the past decade and a half in CH. Among several
mechanisms of actions, triptans have been shown to bind to serotonin (5-HT)1B/1D receptors
and inhibit the release of neuropeptides and inflammatory substrates at the trigeminal
vascular junction. In addition, triptans act on central 5-HT1D receptors to limit activation of
the trigeminal nucleus caudalis and thus may aid in the prevention of central sensitization.
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Like all triptans, sumatriptan is classified as Category C; however, its safety profile has been
documented in pregnancy to a greater extent than other triptans, including exposure in first
trimester [16, 17]. Its relative hydrophilicity makes it more difficult for sumatriptan
(compared with more lipophilic triptans) to traverse the placental membrane. In physiologic
testing, only about 15% of a dose crossed into the fetal compartment over 4 h. With an
average elimination half-life of 2 h, it is evident that only very small amounts will cross
from mother to fetus after a single dose of sumatriptan [18]. Due to significantly lower
maternal serum concentration, the nasal spray formulation would be a logical first choice
route of administration, with advancement to injection if needed for control of attacks.
Other acute options include intranasal installation of lidocaine (pregnancy Category B),
which induces anesthesia in the region of the pterygopalatine fossa and results in rapid relief
with a low side-effect profile [12]. Intranasal dihydroergotamine, although effective in the
general population of CH sufferers, would very rarely, if ever, be advocated in pregnancy, as
it is Category X. Further, symptomatic treatment with metoclopramide (Category B) or
prochlorperazine (Category C) could be employed when necessary.
Thus, in the pregnant patient, oxygen is the most appropriate first-line therapy for acute CH
attacks, with the nasal spray formulation of sumatriptan (Category B) or nasal lidocaine
(Category B) as appropriate second-line therapies when required (Table 2).
Both transitional and traditional preventative options may be required for the treatment of
CH in pregnant women. Transitional preventives are those given to break cluster cycles. In
this capacity, greater occipital nerve (GON) blockade has demonstrated efficacy in acute
CH, and in some cases, will break a cluster cycle. In a small open-label study, 13 of 22 CH
patients treated with GON blockade experienced complete or partial response, with partial
responses lasting an average of 21 days [19]. Treatment was well tolerated with no adverse
events. Although GON blockade has not been specifically tested in pregnancy, it is usually
performed with lidocaine and betamethasone, drugs that are rated Categories B and C,
respectively (Table 2).
The consensus choice of the EFNS for prevention of CH in the general (nonpregnant)
population was verapamil (Category C) at a daily dose of at least 240 mg. In addition to
verapamil, steroids are also generally accepted as effective in CH, despite the lack of
evidence from class I or class II trials. The recommended dosage of methylprednisone
(Category C) is an oral dose of at least 100 mg daily, or an intravenous dosage of up to 500
mg daily over 5 days before tapering.
Topiramate may be an acceptable alternative to verapamil for CH prevention in pregnancy.
Although not well established (primarily due to small sample sizes and design limitations),
several studies have suggested that topiramate may be an effective CH preventive therapy,
with headache remission in 50% to 70% of those with episodic or chronic CH. As it is
pregnancy Category C, topiramate may be of consideration in pregnant CH sufferers when
prevention is required (Table 2) [20•].
Although methysergide (which is no longer available in the United States and is Category
D) and lithium (also Category D) are recommended as alternative treatments in the general
population, they are not generally used in pregnancy unless the benefit to the mother
“clearly exceeds the risk to the fetus,” as harm has been shown in human pregnancies.
Finally, surgical procedures for CH exist, and although promising, require further scientific
scrutiny before formal recommendations can be made.
Thus, in the pregnant patient, verapamil (pregnancy Category C) and steroids (Category C)
remain the preferred options when preventive treatment is required (Table 2).
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Virtually all drugs taken by the mother will be present to some extent in breast milk.
Membrane transport is achieved primarily by passive diffusion, with the classic factors of
concentration gradient, lipophilicity, protein binding, and degree of ionization determining
transport kinetics [21••].
The extent of drug transfer into breast milk is most commonly described quantitatively using
the milk:plasma concentration ratio. The infant dose can thus be calculated and expressed as
a percentage of the maternal dose. For most drugs, an arbitrary cutoff of 10% has been
accepted as a guide to the safe use of drugs in lactation; however, for drugs with greater
inherent toxicity, such as cytotoxic agents, that cutoff would not apply. Rather,
breastfeeding would be contraindicated in their presence. Premature infants have a severely
limited ability to clear drugs, but, in general, if the infant dose—as a percentage of the
maternal dose (corrected for weight)—is close to 1%, the drug can be considered safe
regardless of infant age [21••].
The route of administration is also a factor. Topical creams, nasal sprays, or inhalers usually
convey less exposure to the breastfed infant than oral drugs due to lower maternal
concentrations. Drugs that are poorly absorbed or have high maternal first-pass metabolism
are also less likely to be a concern in lactation, along with very hydrophilic drugs that have
difficulty crossing physiologic membranes into breast milk. Timing breastfeeding to occur
immediately prior to a maternal drug dose may also help to minimize infant exposure, as
drug concentrations in milk tend to be lowest at the end of the dosing interval.
The American Academy of Pediatrics (AAP) Committee on Drugs divides medication usage
in lactation into seven “tables” (To limit confusion we describe what the AAP terms as
“tables” as “categories” of medications in lactation in Table 3.) [22].
The AAP lists sumatriptan as compatible with breastfeeding [22]. Other triptans, many of
which are lipophilic, have not yet been reviewed or received this categorization. Also,
among compatible medications are lidocaine, prednisone, prednisolone, and verapamil.
Additional points of note include the following: 1) Although the AAP has not issued a
position statement for the use of dihydroergotamine in lactation, it considers the use of the
related compound ergotamine to be cause for “caution.” Ergotamine exposure has resulted in
convulsions in the nursing infant. 2) Although metoclopramide is considered relatively safe
in pregnancy (Category B) it is of more concern in lactation, where it is concentrated in
breast milk relative to the maternal serum concentration, and according to the AAP, “may be
of concern.” Prochlorperazine, as all phenothiazines, are similarly categorized as “may be of
concern” (Table 3). 3) Finally, particular caution should be exercised with lithium, as it
crosses readily into breast milk at levels considerably higher than the referenced 10% cutoff
figure—in some cases up to 50% of the maternal dose [22]. The long-term outcome is
unknown, and prescription of lithium to lactating women is controversial [23]. Although
there is no absolute contraindication, it is known that the kidney is particularly sensitive to
lithium just after birth, and cases of renal toxicity have been reported.
Thus, the preferred agents for acute treatment of CH during lactation would include oxygen,
sumatriptan, and lidocaine; for prevention, prednisone/prednisolone and verapamil would be
appropriate first options when required (Table 2) [24].
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Cluster headache (CH) is a relatively uncommon neurovascular headache syndrome
characterized by headache attacks that occur with a regular periodicity. Although CH during
pregnancy is a relatively rare condition, the data suggest that when it does occur, attacks
remain unchanged in character and severity in the majority of patients. Thus, treatment of
CH in pregnant and lactating women may present a significant therapeutic challenge.
Nevertheless, when nonpharmacological agents are not sufficient, it is reassuring that many
of our standard first-line therapies for treatment of CH remain viable options in the pregnant
and lactating woman who suffers from these debilitating attacks.
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Appendix 1 Berlin questionnaire
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Appendix 2 Pittsburgh sleep quality index
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Appendix 3 Pittsburgh sleep quality index references and scoring
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Table 1
FDA medication categories in pregnancy
Category Interpretation
A Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities to the fetus in any
trimester of pregnancy.
B Animal studies have revealed no evidence of harm to the fetus; however, there are no adequate and well-controlled studies in
pregnant women.
OR
Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to
demonstrate a risk to the fetus in any trimester.
C Animal studies have shown an adverse effect, and there are no adequate and well-controlled studies in pregnant women.
OR
No animal studies have been conducted, and there are no adequate and well-controlled studies in pregnant women.
D Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits
of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or
serious disease for which safer drugs cannot be used or are ineffective.
X Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal
abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.
FDA US Food and Drug Administration
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Table 2
Pharmacologic recommendations for treatment of cluster headache in pregnant or lactating women
FDA pregnancy category AAP lactation category Authors' recommendation Note
Acute abortive therapy
 Oxygen N/A N/A First line for both pregnancy
and lactation
–
 Sumatriptan (intranasal) C 6: usually compatible Second line for both
pregnancy and lactation









 Lidocaine (intranasal) B 6: usually compatible Second line for both
pregnancy and lactation








Metoclopramide B 4: may be of concern Third line during pregnancy
and lactation
Metoclopramide
has not been proven
effective for CH
and thus is listed as






 GON blockade (using
lidocaine and
betamethasone)











 Verapamil C 6: usually compatible First line for both pregnancy
lactation
–
 Steroids C 6: usually compatible First line for both pregnancy
and lactation
–
 Topiramate C Has not been reviewed
by the AAP












 Lithium D 5: caution Third line for both pregnancy
and lactation; should be used
only when benefit clearly
exceeds risk
–
AAP American Academy of Pediatrics, CH cluster headache, FDA US Food and Drug Administration, GON greater occipital nerve
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Table 3
The American Academy of Pediatrics Committee tables on drugs compatible with breastfeeding
a
1. Cytotoxic drugs that may interfere with cellular metabolism of the nursing infant
2. Drugs of abuse for which adverse effects on the infant during breastfeeding have been demonstrated
3. Radioactive compounds that require temporary cessation of breastfeeding
4. Drugs for which the effect on nursing infants is unknown, but may be of concern
5. Drugs that have been associated with significant effects on some nursing infants and should be given to nursing mothers with caution
6. Maternal medication usually compatible with breastfeeding
7. Food and environmental agents
a
The American Academy of Pediatrics lists these seven points or categories as “tables” of drugs
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